David Cordani - Mar 7, 2024 Form 4 Insider Report for Cigna Group (CI)

Role
Chairman & CEO, Director
Signature
Matthew Arnold, attorney-in-fact
Stock symbol
CI
Transactions as of
Mar 7, 2024
Transactions value $
-$1,075,022
Form type
4
Date filed
3/11/2024, 05:38 PM
Previous filing
Mar 5, 2024
Next filing
Mar 14, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CI Common Stock, $.01 Par Value Options Exercise $336K +2.41K +0.71% $139.22 343K Mar 7, 2024 Direct F1
transaction CI Common Stock, $.01 Par Value Sale -$208K -600 -0.18% $346.65 342K Mar 7, 2024 Direct F1, F2
transaction CI Common Stock, $.01 Par Value Sale -$626K -1.81K -0.53% $345.42 340K Mar 7, 2024 Direct F1, F3
transaction CI Common Stock, $.01 Par Value Options Exercise $390K +2.8K +0.82% $139.22 343K Mar 8, 2024 Direct F1
transaction CI Common Stock, $.01 Par Value Sale -$967K -2.8K -0.82% $345.19 340K Mar 8, 2024 Direct F1, F4
holding CI Common Stock, $.01 Par Value 1.73K Mar 7, 2024 By 401(k) F5
holding CI Common Stock, $.01 Par Value 99.9K Mar 7, 2024 By GRAT
holding CI Common Stock, $.01 Par Value 154K Mar 7, 2024 By Trust

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CI Employee Stock Option (Right to Buy) Options Exercise $0 -2.41K -3.16% $0.00 74K Mar 7, 2024 Common Stock, $.01 Par Value 2.41K $139.22 Direct F1, F6
transaction CI Employee Stock Option (Right to Buy) Options Exercise $0 -2.8K -3.78% $0.00 71.2K Mar 8, 2024 Common Stock, $.01 Par Value 2.8K $139.22 Direct F1, F6
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 15, 2023.
F2 Represents the weighted average price of the shares sold. The prices actually received ranged from $346.07 to $346.99 per share. The reporting person will provide to the issuer, any security holder of the issuer, or the Securities and Exchange Commission, upon request, information regarding the number of shares sold at each price within the range.
F3 Represents the weighted average price of the shares sold. The prices actually received ranged from $345.00 to $345.92 per share. The reporting person will provide to the issuer, any security holder of the issuer, or the Securities and Exchange Commission, upon request, information regarding the number of shares sold at each price within the range.
F4 Represents the weighted average price of the shares sold. The prices actually received ranged from $345.00 to $345.82 per share. The reporting person will provide to the issuer, any security holder of the issuer, or the Securities and Exchange Commission, upon request, information regarding the number of shares sold at each price within the range.
F5 Represents shares acquired through ongoing participation in The Cigna Group's 401(k) Plan.
F6 This option was granted on March 1, 2016. The option vested in three equal annual installments on the first, second and third anniversaries of the grant date.